Azome Therapeutics to Present at MedInvest Biotech & Pharma Investor Conference

March 29, 2024

Azome Therapeutics, an early-stage drug development company, announced today that the company will present at the upcoming MedInvest Biotech & Pharma Investor Conference from April 3-4, 2024 in New York, NY.

One of more than 40 companies presenting at this year’s conference, Azome Therapeutics will highlight the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152.  This novel antagonist platform, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several that have significant unmet needs.

Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azome Therapeutics Selected to Present at 2024 Florida Venture Capital Conference

January 18, 2024

Azome Therapeutics, an early-stage drug discovery company, announced today that the company has been selected to present at the upcoming 2024 Florida Venture Capital Conference from January 31 - February 1, 2024, in Miami, FL.  

One of 60 presenting companies, Azome Therapeutics, will highlight the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152.  This novel antagonist platform, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several that have significant unmet needs.

Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azome Therapeutics Selected to Present at Biotech Showcase 2024

January 2, 2024

Azome Therapeutics, an early-stage drug discovery company, announced today that the company has been selected to present at the upcoming Biotech Showcase 2024, a premier investor conference, from January 8-10, 2024 in San Francisco, CA.  

More than 3,500 international investors and companies are expected to attend this year’s Biotech Showcase. Azome Therapeutics is one of approximately 350 companies that have been selected to present during the 2-day event.

The Azome presentation will highlight positive preclinical research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform, which blocks inflammasome activation, and its lead drug candidate, AZM-152.

“We are very excited to be one of the select companies invited to present at this year’s showcase,” said Azome Therapeutics CEO Elliott Gruskin, PhD.  “Based on the latest research we will be presenting, our RHAMM antagonist platform is demonstrating excellent potential for advancing the treatment of severe inflammatory diseases, including several that have significant unmet needs.”

Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.